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Abstract
The costs of medicines pose a growing burden on healthcare systems worldwide. A compre-
hensive understanding of current procurement processes provides strong support for the
development of effective policies. This study examined Brazilian Federal Government phar-
maceutical procurement data provided by the Integrated System for the Administration of
General Services (SIASG) database, from 2006 to 2013. Medicine purchases were aggre-
gated by volume and expenditure for each year. Data on expenditure were adjusted for infla-
tion using the Extended National Consumer Price Index (IPCA) for December 31, 2013.
Lorenz distribution curves were used to study the cumulative proportion of purchased thera-
peutic classes. Expenditure variance analysis was performed to determine the impact of
each factor, price and/or volume, on total expenditure variation. Annual expenditure on med-
icines increased 2.72 times, while the purchased volume of drugs increased 1.99 times. A
limited number of therapeutic classes dominated expenditure each year. Drugs for infec-
tious diseases drove the increase in expenditures from 2006 to 2009 but were replaced by
antineoplastic and immunomodulating agents beginning in 2010. Immunosuppressants
(L04), accounted for one third of purchases since 2010, showing the most substantial
growth in expenditures during the period (250-fold increase). The overwhelming price-
related increase in expenditures caused by these medicines is bound to have a relevant
impact on the sustainability of the pharmaceutical supply system. We observed increasing
trends in expenditures, especially in specific therapeutic classes. We propose the develop-
ment and implementation of better medicine procurement systems, and strategies to allow
for monitoring of product price, effectiveness, and safety. This must be done with ongoing
assessment of pharmaceutical innovations, therapeutic value and budget impact.
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Introduction
Medicines represent one of the largest and fastest growing costs for healthcare systems world-
wide. According to data from 161 WHO Member States from 1995 to 2006, per capita spend-
ing on pharmaceuticals has increased by approximately 50%, and these increments were more
pronounced in middle-income countries, where pharmaceutical expenditure in 2006 was1.76
times greater than in 1995 [1].
Ensuring and expanding access to quality medicines at affordable prices, with adequate
financing require an effective healthcare supply system. Ideally, this system should include the
selection of reliable suppliers of assured-quality products and the procurement of safer and
more cost-effective medicines in the right quantities at the lowest possible total cost to the sys-
tem optimal and timely delivery [2].
Ageing populations and increasing expenditures on new drugs place considerable pressure
on healthcare systems in their efforts to continue to provide comprehensive care [3]. Conse-
quently, not only should cost-effectiveness analyses for the introduction of all new medicines
must be made, but new models for the introduction of expensive medicines are needed, as well
as effective management of essential medicines for treating common diseases like hyperten-
sion, diabetes, and respiratory, cardiovascular and infectious diseases in general [4]. This
requires efficient and transparent procurement procedures.
However, achieving these purposes requires a proper balance between the conflicting policy
goals of access to medicines and budget control. A comprehensive understanding of how pro-
curement is being conducted, considering price, volume and treatment regimen, the three
main components typically identified as affecting pharmaceutical spending [1, 5–7], provides
strong support for the development of effective policies.
Medicines policy has been a key part of Brazil’s healthcare system since 1998. In that year,
the National Medicines Policy was published, and from then on various additional policy doc-
uments and norms were added to the legal framework. Medicines policy in Brazil comprises
today a wide berth of regulations that influence industrial policies, all regulatory actions, medi-
cines procurement and availability, and medicines utilization in the health system and by indi-
viduals. As an upper middle-income country with one of the largest healthcare systems in the
world, committed to universal access to medicines, Brazil faces several challenges. Besides its
complex administrative structure regarding medicines procurement procedures—conducted
independently by more than 5,500 municipalities, 26 states and the Federal District, the Fed-
eral Government, as well as hospitals under indirect public administration—, a large portion
of medicines expenditures is out-of-pocket and most private health insurance plans fail to
cover medicines [8]. The analysis of medicines expenditures must be performed, thus, for each
public level to identify potential problems and formulate adequate and cost-effective policies
[9].
Such analyses require access to high-quality data on pharmaceutical expenditure, which has
generally been lacking for low- and middle-income countries [1]. This study addresses this gap
by examining public medicine procurement in Brazil. Trends in purchases from 2006 to 2013
both in general and by different therapeutic groups were evaluated to identify the key drivers
of increases or decreases in spending.
Methods
Data source
Data for this study were obtained from the Integrated System for Administration of General
Services/Sistema Integrado de Administração de Serviços Gerais (SIASG) database. SIASG is a
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publicly available general procurement database of the Brazilian federal government (http://
dados.gov.br/dataset/compras-publicas-do-governo-federal). Our data included medicines
purchases by all federal government bodies (Ministries of Health, Defense, Education, and Jus-
tice, among others).
We analyzed pharmaceutical purchases from January 2006 to December 2013. These were
considered the most consistent data for two reasons: (1) the SIASG registry protocol was
updated in 2005 and (2) 2013 was the last full year of available data when the study began.
Data were extracted for all medicines. Every purchase is individually described in the database
with information on the drug (name, dosage form and strength), unit purchase price, and pur-
chased quantity in number of drug packaging units.
Analysis
In order to evaluate procurement trends from 2006 to 2013 both in general and by different
therapeutic groups and to identify the key drivers of increases or decreases in expenditure, we
conducted several analyses.
All pharmaceutical products were classified in accordance with the WHO-ATC/DDD sys-
tem coordinated by the WHO Collaborating Centre for Drug Statistics Methodology. The
ATC system classifies medicines in groups at five levels, starting by fourteen main groups, fol-
lowed by pharmacological/therapeutic subgroups (2nd level), chemical/pharmacological/thera-
peutic subgroups (3rd and 4th levels) and the chemical substance (5th level). The ATC
classification is used worldwide for comparison of drug consumption and as a tool for drug
utilization research[10]. Analyses were conducted at two different ATC levels: anatomical
main group (ATC 1st level) and therapeutic groups (ATC 2nd level). Descriptive statistics
expressing data as frequencies and percentages were estimated using SPSS 22.0 for Windows
(IBM Corporation, USA) and Microsoft Excel 2007.
Expenditure and volume estimations
Medicine purchases were aggregated by volume (number of drug packaging units purchased)
and expenditure (number of drug packaging units purchased multiplied by unit purchase
price) for each year from 2006 to 2013.
Data on expenditure were adjusted for inflation using the Extended National Consumer
Price Index (IPCA) with December 31, 2013, as the reference date. This index is provided by
the Brazilian Institute of Geography and Statistics (IBGE) [11] and is used by the Brazilian
Central Bank. Expenditure was measured in US Dollars (USD) (1 USD = 2.3426 Brazilian
Reais (BRL), December 31, 2013).
Lorenz curves
Lorenz curves were used to study the cumulative proportion of drug purchases by therapeutic
groups [12]. Purchases were ranked in descending order by expenditure. The cumulative per-
centage of expenditure was plotted along the vertical axis versus the cumulative percentage of
therapeutic classes (ATC 2nd level) purchased on the horizontal axis. Differences in expendi-
tures on purchased therapeutic classes can be identified by visual inspection of the curve. A
diagonal line is expected if all therapeutic classes are being purchased in similar amounts, and
the curve deviates from this diagonal when it indicates the existence of quantitative differences
in spending on each class. We analyzed the Lorenz 1st and 50th percentiles, i.e., the proportions
of total expenditure that 1% and 50% of all therapeutic groups accounted for, respectively.
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Expenditurevariance analysis
Expenditure variance analysis is a descriptive method designed to compare performance to
budgets (i.e. expected values) in a given time period. The components of an expenditure vari-
ance can be divided into two broad elements: price variance and volume variance[13,14].
Considering the medicines purchase process, expenditure variance may be a result of pay-
ing more or less than the standard for a given product—price variance component—or of an
increase or decrease in the quantities purchased—volume variance component—or of a com-
bination of the two factors [13,14].
To determine the impact of each factor, purchase price and volume, on total expenditure
variation from 2006 to 2013, actual and standard average unit purchase prices (AP and SP),
were calculated by dividing total expenditure by total volume purchased, aggregated by thera-
peutic class, for each of the top 20 therapeutic classes. Prices were corrected by the Extended
National Consumer Price Index (IPCA) as mentioned previously. Purchased quantity and
average unit purchase price from 2006 were considered as standards, SQ and SP, respectively,
while data from 2013 provided information on actual quantity purchased (AQ) and actual
average unit purchase price (AP).
The price, volume and expenditure variances were computed using the following formulas:
Price variance ¼ ðAQ  APÞ   ðAQ  SPÞ
Where:
AQ is ‘actual quantity purchased’
AP is ‘actual average unit purchase price’
SP is ‘average unit purchase price’
Volume variance ¼ ðAQ  SPÞ   ðSQ SPÞ
Where:
AQ is ‘actual quantity purchased’
SP is ‘average unit purchase price’
SQ is ‘purchased quantity’
Expenditure variance ¼ ðAQ  APÞ   ðSQ SPÞ
Where:
AQ is ‘actual quantity purchased’
AP is ‘actual average unit purchase price’
SP is ‘average unit purchase price’
SQ is ‘purchased quantity’
Ethical aspects
The study analyzed publically available data and did not involve human subjects, specimens or
tissue samples, or vertebrate animals, embryos, or tissues. There was no need of prior approval
by an Institutional Review Board.
Results
From 2006 to 2013, the Brazilian Federal Government purchased, nearly 23 billion drug pack-
aging units (Table 1) belonging to 15 different anatomical main groups (ATC 1st level) and 90
different therapeutic groups (ATC 2nd level). The total medicine expenditure, adjusted for
inflation, was USD 14.7 billion (BRL 34.6 billion) during the period (Table 1). Annual
Trends in medicines procurement by the Brazilian federal government
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expenditure increased 2.72 times (172%) from 2006 to 2013, while volume increased 1.99
times (100%). The top twenty therapeutic groups accounted for more than 90% of total expen-
diture and volume each year (Table 1).
During the period, there was considerable variation in the use of different drug classes. In
2006, cardiovascular drugs (ATC main group C) accounted for the largest proportion of vol-
umes while drugs for treating infectious diseases (ATC main group J) dominated expenditures
(Fig 1). In 2013, cardiovascular drugs were the most important class in terms of volume, while
antineoplastic and immunomodulating agents (ATC main group L) emerged as the main
group in expenditures. Antineoplastic and immunomodulating agents (L) were the therapeutic
class with the broadest variation during the period, with a 20-fold increase in expenditure
from 2006 to 2013, from USD78.2 million (BRL183.2 million) to USD1.57 billion (BRL3.7
billion).
A limited number of therapeutic areas dominated expenditure each year (Fig 2) and the
therapeutic groups constituting the 1% percentile and the 50% percentile of the Lorenz curve
only showed minor variation. From 2006 to 2009, antivirals (J05) constituted the 1% percentile
whereas from 2010 to 2013, immunosuppressants (L04) became the main class. Any class at
the curve’s 1% percentile accounted for approximately thirty percent of total expenditure,
regardless of the year. A few therapeutic groups constituted half of total expenditure (50% per-
centile of the Lorenz curve): antivirals (J05) and various enzymes/amino acids (A16) in 2006
and immunosuppressants (L04), antineoplastic (L01) and antivirals (J05) in 2013. Considering
the entire period (2006–2013), just three therapeutic groups (immunosuppressants, antivirals,
and antineoplastic agents) dominated expenditure, constituting the curve’s 50% percentile (see
also Table 2).
Table 2 shows the top 20 therapeutic classes in terms of expenditure, purchased from 2006
to 2013. These classes came from eight main groups (A, B, C, G, J, L, N, and V). While most
classes (n = 17) showed an increase in expenditure, ranging from 43% for anti-hemorrhagic
agents to 250 times for immunosuppressants (25098.7%), the reduction in spending in the
remaining three classes varied from 16.8% (alimentary tract and metabolism) to 94% (other
therapeutic groups).
Table 3 shows the results of expenditure variance analysis. For the majority of the therapeu-
tic classes (n = 11), price variance was the main factor explaining expenditure variance during
the period 2006–2013.
Price and volume varied in the same direction for nine therapeutic classes. Of those, seven
classes (L04, L01, B02, A16, J01, J02, and L02) showed price variance as the primary factor
contributing to expenditure. For example, the main reason for the increase in spending on
Table 1. Annual total and by top 20 medicine expenditures and total purchase volume in drug packaging units. Brazil, 2006–2013.
Year Total expenditureUS$ Top 20 expenditureUS$ Total volume Top 20 volume
US$ (%) US$ (%)
2006 1,124,158,372 1,052,500,608 93.6 2,070,642,460 1,933,132,953 93.4
2007 1,116,143,137 1,054,406,762 94.5 1,881,582,657 1,700,828,887 90.4
2008 1,126,058,529 1,054,840,245 93.7 3,028,162,544 2,866,179,975 94.7
2009 1,633,804,693 1,521,550,673 93.1 2,008,236,794 1.832.744.729 91.3
2010 1,755,370,595 1,658,063,509 95.5 4,182,515,053 3,863,864,788 92.4
2011 2,653,708,350 2,548,087,364 96.0 2,650,220,185 2,460,961,517 92,9
2012 2,327,737,837 2,223,653,812 95.5 3,054,801,562 2,884,111,304 94,4
2013 3,053,794,154 2,887,769,786 94.2 4,123,525,494 3,700,593,751 89.7
Total 14,790,775,666 14,000,872,759 94.7 22,999,686,749 21,242,417,904 92.4
https://doi.org/10.1371/journal.pone.0174616.t001
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immunosuppressants (L04), antineoplastic agents (L01), and antimycotics for systemic use
(J02) during the period was price variation, which explained 73.7%, 55.0%, and 98.5% of
expenditure variance, respectively.
For two therapeutic classes (A10, N01), volume variance was the main driver of expenditure
variance. In the case of A10 drugs (used in diabetes), volume variance accounted for almost
60% of expenditure variance (nearly USD104 million).
Eleven therapeutic classes showed price and volume variances in opposite directions
(Table 3). For three therapeutic classes (J05, B03, B01), the effect of price reduction was nearly
counterbalanced by volume variance, but still prevailed. For class C10 (lipid modifying agents),
there was a volume reduction, but the price increased over time. For the remaining seven clas-
ses (J07, L03, J06, B05, G03, V03, V08), volume variance attenuated the effect of price decrease
over time.
Discussion
Our findings suggest a significant increase in pharmaceutical expenditure by the Brazilian
Federal Government from 2006 to 2013. Total expenditure practically tripled, while the quan-
tities purchased only doubled during this eight-year period. This tendency of growth in
Fig 1. Volume and expenditure by major classes of medicines. Brazil, 2006–2013.
https://doi.org/10.1371/journal.pone.0174616.g001
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pharmaceutical spending is being observed worldwide, but at different rates [15–19]. In Can-
ada, from 2006 to 2011, government medicines expenditures increased at an average annual
rate of 4.5% [17], while in Brazil the rate was 13.3% per year. In China, a similar (14.9%) yet
non-deflated annual growth rate for total drug expenditure was observed for the period 1990–
2009 [18].
The main factors that can drive up expenditure on pharmaceuticals in a country are high
purchase prices, high-use patterns (i.e. quantity), or a combination of the two [1, 5–7].
Switches to new therapies and an adopted high-priced treatment regimen, as in Brazil, are defi-
nite explanatory factors. This is corroborated by reports from the National Committee for
Health Technology Incorporation (CONITEC, formerly CITEC). According to these reports,
60% of medicines incorporated by the Brazilian Health System (SUS) from 2012 to 2016 were
high-priced products [20].
A few classes dominated expenditures during the period in question, and price-related
determinants strongly affected drug expenditure. Despite variation in the use of different drug
classes, a common issue was the replacement in the ranking over time, of less expensive medi-
cines, such as those for treating infectious diseases (J), with newer, more costly and patent-pro-
tected medicines, such as antineoplastic and immunomodulating agents (L). These results are
in line with findings from other countries [21, 22].
Fig 2. Lorenz curves from Brazilian federal government purchases. Brazil, 2006–2013. Number of therapeutic classes: 90 (ATC 2nd level) 1%
Percentiles of Lorenz curves: J05 (2006); L04 (2013; 2006–2013). 50% Percentiles of Lorenz curves: J05, A16 (2006); L04, L01, J05 (2013); L04, J05,
L01 (2006–2013).
https://doi.org/10.1371/journal.pone.0174616.g002
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Immunosuppressants (L04) include anti-TNF-α (tumor necrosis factor alpha) drugs and
interleukin inhibitors. These drugs, used to treat rheumatoid arthritis (worldwide prevalence
rate estimated at 0.5–1.0% of the population) and Crohn’s disease (estimated incidence rate
6.3/100,000 person-years) [17, 23, 24], showed the most substantial expenditure increase, with
more than 250 times (25098.7%), accounting for one third of purchases since 2010. For this
Table 2. Top 20 therapeutic classes by annual expenditure, by total expenditure in the period, and by expenditure variation (in USD). Brazil, 2006–
2013.
Therapeutic class 2006 2007 2008 2009 2010 2011 2012 2013 Total 2006–
2013
Expenditure variation
(%)
L04—immunosuppressants 3.4 9.8 14.6 8.6 703.1 956.8 611.9 858.9 3166.9 25098.7a
J05—antivirals for systemic use 320.1 208.4 229.7 594.1 84.2 229.5 331.6 243.1 2240.7 -24.0
L01—antineoplastic agents 43.7 81.2 82.5 105.9 152.6 349.0 164.3 478.4 1457.6 993.6b
B02—anti-hemorrhagic agents 134.8 101.9 126.4 135.2 116.5 243.4 234.7 192.6 1285.5 42.9
L03—immunostimulants 22.3 158.4 143.7 129.8 134.1 264.0 157.2 204.9 1214.4 819.4c
A16—other alimentary tract and metabolism
products
238.7 7.4 109.4 149.3 92.6 161.4 123.4 198.5 1080.7 -16.8
J07—vaccines 0.2 175.6 6.0 94.5 51.0 8.3 199.6 45.9 581.2 19347.4d
A10—drugs used in diabetes 54.9 86.4 48.7 32.0 30.2 5.3 62.6 158.8 478.8 189.3e
J06—immune sera and immunoglobulins 43.0 44.2 71.5 46.9 12.2 88.5 12.8 88.9 408.1 106.8f
J01—antibacterials for systemic use 42.2 32.9 34.6 53.0 54.8 50.2 59.5 75.0 402.4 77.7
J02—antimycotics for systemic use 9.5 20.5 26.6 23.8 32.5 32.5 62.9 70.4 278.7 639.8g
B05—blood substitutes and perfusion solutions 13.3 24.4 33.1 39.2 35.8 40.4 28.7 57.1 272.0 329.7h
G03—sex hormones and modulators of the
genital system
3.6 22.1 25.0 5.8 38.7 19.8 26.2 39.7 180.8 1013.2i
B03—antianemic preparations 57.6 28.7 36.0 1.5 1.4 2.3 32.6 3.5 163.6 -94.0
V03—all other therapeutic products 1.1 1.5 2.5 22.7 29.5 3.4 47.2 45.2 153.0 3997.8j
B01—antithrombotic agents 8.4 9.3 14.4 17.7 15.6 20.6 21.3 36.0 143.3 331.0k
L02—endocrine therapy 8.8 12.5 11.6 14.5 13.8 14.4 13.0 27.2 115.9 210.1l
N01—anesthetics 7.4 13.4 8.3 13.2 10.9 15.7 14.0 20.2 103.2 174.8m
V08—contrast media 4.0 6.7 14.3 13.4 8.5 10.6 7.7 8.6 73.7 117.3n
C10—lipid modifying agents 5.2 2.2 9.1 2.0 13.6 9.9 10.8 8.3 61.3 59.0
Expenditures are presented in USD million (1 USD = 2.343 BRL)
Expenditure variation = (2013–2006)/2006
Percentages higher than 100% can also be described in terms of "x fold increase". Converted percentages were rounded off accordingly:
a: 250 fold increase;
b: 9.9 fold increase;
c: 8.2fold increase;
d: 193 fold increase;
e: 1.9 fold increase;
f: 1.1 fold increase;
g: 6.4 fold increase;
h: 3.3 fold increase;
i: 10 fold increase
j: 40 fold increase;
k: 3.3 fold increase;
l: 2 fold increase;
m: 1.7 fold increase;
n: 1.2 fold increase
https://doi.org/10.1371/journal.pone.0174616.t002
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class, price was the main factor boosting expenditure. Many high-priced new medicines were
introduced in this class. This finding corroborates previous literature. Anti-TNF drugs were
one of the classes that most contributed to the growth of public drug spending in Canada
between 2007 and 2012, reaching 54.8% [17].
The overwhelming price-related increase caused by L04 class is bound to have an impor-
tant impact on the sustainability of Brazil’s pharmaceutical supply system. If price reduction
strategies are not implemented, Brazil’s selection, incorporation, and purchase of high-priced
innovative drugs, e.g., the recently adopted direct acting antivirals (DAAs) for hepatitis C
(sofosbuvir, daclastavir, and simeprevir), may challenge the continuity of provision, given
the same level of financing, if other access mechanisms such as generic production cannot be
achieved [25]. Furthermore, the new medicines are under patent protection, and competition
is limited or nonexistent [20, 26, 27].
Volume was the main driver of expenditure for a few therapeutic classes, such as immunos-
timulants, vaccines, drugs used in diabetes, sex hormones, modulators of the genital system,
and anesthetics. These results may reflect an increase in coverage, whereby more patients can
take advantage of the provision of these medicines. Such gains may reflect either economies of
scale in procurement procedures, therapeutic reference pricing, or generic substitution. Part of
Table 3. Price and volume variances and results of expenditure variance analysis by therapeutic subgroup. Brazil, 2006–2013.
Therapeutic subgroup Price variancea Volumevarianceb Expenditure variancec
Value % Value %
L04—immunosuppressants 630.8 73.7 224.7 26.3 855.4
J05—antivirals for systemic use -644.8 838.2 567.8 -738.2 -76.9
L01- antineoplastic agents 238.7 54.9 195.9 45.1 434.6
B02-anti-hemorrhagic agents 52.9 91.5 4.9 8.5 57.9
L03- immunostimulants -282.8 -154.9 465.4 254.9 182.6
A16—other alimentary tract and metabolism products -33.1 82.4 -7.1 17.6 -40.2
J07—vaccines -56.0 -122.6 101.6 222.6 45.7
A10—drugs used in diabetes 41.7 40.2 62.2 59.8 103.9
J06—immune sera and immunoglobulins -114.2 -248.7 160.1 348.7 45.9
J01- antibacterials for systemic use 26.9 82.1 5.9 17.9 32.8
J02 antimycotics for systemic use 59.9 98.5 0.9 1.5 60.9
B05—blood substitutes and perfusion solutions -4.1 -9.3 47.9 109.3 43.8
G03—sex hormones and modulators of the genital system -159.5 -441.6 195.6 541.6 36.1
B03—antianemic preparations -121.0 223.7 66.9 -123.7 -54.1
V03—all other therapeutic products -202.9 -460.6 247.0 560.6 44.0
B01—antithrombotic agents 27.9 100.8 -0.2 -0.8 27.7
L02—endocrine therapy 11.1 60.2 7.3 39.8 18.4
N01—anesthetics 0.2 1.7 12.6 98.3 12.9
V08—contrast media -4.8 -103.9 9.5 203.9 4.6
C10—lipid modifying agents 3.2 104.1 -0.1 -4.1 3.1
Expenditures are presented in USD million (1 USD = 2.343 BRL).
AQ = actual quantity purchased; AP = actual average unit price; SQ = standard quantity purchased; SP = standard average unit price
a(AQ2013 x AP2013)—(AQ2013 x SP2006);
b(AQ2013 x SP2006)—(SQ2006 x SP2006);
c(AQ2013 x AP2013)—(SQ2006 x SP2006)
https://doi.org/10.1371/journal.pone.0174616.t003
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this increase may also be explained by the introduction of new medicines to treat previously
untreatable diseases within these classes [22].
In general, confronting the great concentration of purchases on a few therapeutic classes
within the Brazilian burden of disease suggests that the federal government should reorient
medicines procurement policies and strategies. Technology adoption in the country, presently
led by the National Committee for Health Technology Incorporation (CONITEC), might
profit by focusing more on the country’s epidemiological profile, where leading causes such as
cardiovascular diseases, mental disorders (particularly depression), diabetes, and chronic
obstructive pulmonary disease account for more than 50% of the disease burden [28].
The main purpose of this article was to estimate medicine expenditure by the Brazilian Fed-
eral Government and examine procurement trends from 2006 to 2013. This was the first study
to analyze expenditure by therapeutic classes and to disaggregate the drivers of spending
growth or decline within each of the major classes.
While some cost-management strategies were adopted by the Brazilian government during
the period in question, the study illustrates some of their potential pitfalls. CONITEC produces
therapeutic protocols and a federal medicines list, which are, by law, the basis for medicines
financing and prescription in the public healthcare system. Notwithstanding, physicians
throughout the system make individual therapeutic choices that impact expenditures. The
medicines selection process is not accepted by all and suffers greatly from pressures for inno-
vation [29].
Other factors may also be involved, from lack of the necessary purchaser’s power in price
negotiations [1, 30–32], as befalls many other financially constrained middle-income coun-
tries, to inadequate revision and faulty adherence to therapeutic guidelines [1].
We presented a detailed picture of medicine purchases by the Brazilian federal government.
Although the article addresses trends in medicines procurement over time, some caveats
deserve consideration. First, SIASG is a national database that registers medicine purchases
and does not allow an assessment of dispensed/prescribed medicines at the individual patient
level, so the estimates are a proxy for actual consumption. Considering the complexity of the
administrative structure for medicine procurement procedures in Brazil, it is presumed that
these analyses represent about one third of drug procurement in the country [9, 33], a consid-
erable amount. Additionally, SIASG does not offer any margins or mark-up values, such as dis-
tribution margins, service fees etc. Therefore we cannot estimate costs for the healthcare
system, only direct drug expenditures (volume x price). In market competition situations, sig-
nificant differences between drug price and drug production cost can considerably burden
health system expenditures[34].
We classified medicines according to the Anatomical Therapeutic Chemical (ATC) classifi-
cation. However, we could not assign a Defined Daily Dose(DDD) for some medicines for
which there are no available DDDs, thus limiting comparisons. Importantly, we did not ana-
lyze individual medicinal products, and our interpretation of the observed changes presumed
utilization by aggregated therapeutic classes over time.
Nevertheless, we believe our results are valuable for elucidating drug procurement practices
by the Brazilian Federal Government’and consequently by the entire public sector in the coun-
try, which is all subject to binding legislation and regulations. SIASG is a large federal procure-
ment database that can be used for planning and forecasting. Given the trends in expenditures
and the rise within specific therapeutic classes, it is important that guidance in drug procure-
ment strategy be developed and implemented, including systems that allow monitoring prod-
uct price, effectiveness, and safety, as well as assessment of pharmaceutical innovations,
therapeutic value, and budget impact.
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